Our Q2 2026 results are now available.
Read the full press release for detailed insights: spkl.io/60197KQtR
#SanofiResults $SAN $SNY
Sanofi
@sanofi
An R&D driven, AI-powered biopharma company committed to improving lives and delivering compelling growth. Terms for interactions: bit.ly/sanofi-terms
- #NEWS: Update on our phase 3 program in moderate-to-severe #AtopicDermatitis. Learn more ⬇️ spkl.io/60127JNVK
- #NEWS: Our phase 3 results show our medicine met its primary and secondary endpoints in treatment-naïve infants with infantile-onset Pompe disease (IOPD). Read more: sanofi.com/en/media-room/…
- #NEWS: The Japan Ministry of Health, Labour and Welfare has approved the first oral, reversible BTK inhibitor to treat adults with immune thrombocytopenia (ITP) who are refractory to other treatments. Read more ⬇️: sanofi.com/en/media-room/…
- #NEWS: The @EU_Commission has approved our medicine for the treatment of certain people with secondary progressive #MultipleSclerosis , reinforcing our commitment to advancing scientific innovation that address unmet patient needs. Learn more ⬇️ sanofi.com/en/media-room/…
